Fairvalue-Calculator Fairvalue-Calculator
EN DE

Kura Oncology, Inc (KURA) Fair Value & Analysis

Healthcare · US · Market cap $882M

Price$10.38
Fair Value$8.83
Upside-14.9%
Quality95/100
Evidence: Low Range $6.62 – $11.03

Fair value as of: Jun 24, 2026

Analysis

Kura Oncology, Inc (KURA) currently trades at $10.38, while our model-based Fair Value estimate is $8.83 — implying the stock looks roughly 14.9% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Kura Oncology, Inc (KURA) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $8.83 versus a price of $10.38 — about −15% (overvalued). Model-based estimate, not financial advice.
What is the fair value of KURA?
Our 21-model fair value for Kura Oncology, Inc is $8.83 (as of Jun 24, 2026), built from audited fundamentals. The current price is $10.38.
What is the quality score of KURA?
Kura Oncology, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.